Pharma Sector

The Delhi High Court reinstated the Centre's 2018 ban on certain diabetes fixed-dose combination drugs, ruling that the law allows action based on potential health risks

IPA member firms have committed $50 million to launch PAGE, an industry-led academy to boost pharmaceutical manufacturing skills, quality systems and regulatory compliance in India

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

With India importing about 70 per cent of its medical devices, the Department of Pharmaceuticals has invited proposals under two sub-schemes to reduce import dependence and support clinical studies

The health ministry is unlikely to extend the revised Schedule M GMP deadline for MSME drugmakers beyond December 31, 2025, as it consults states ahead of risk-based inspections

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Firms not complying with norms risk shutdowns once inspections begin next year

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

India's pharmaceutical industry is stepping into 2026, marking the beginning of a critical five-year period to build the required ecosystem to establish itself as an innovation hub in its bid to become a USD 500 billion sector by 2047, amid near-term challenges of tariff fluctuations and global trade realignments. The predominantly generic medicines-driven domestic drug industry, which has grown from USD 3 billion to USD 60 billion in size over the past 25 years, is shifting towards innovation in next-generation drugs. At the same time, it will also seek to capitalise on the opportunity to capture drugs worth over USD 300 billion that are set to lose exclusivity over the next seven years. "Today, Indian pharma stands at a defining moment and the next 25 years will be shaped by innovation, quality, and access," Indian Pharmaceutical Alliance Secretary General Sudarshan Jain said. The innovation agenda has gained notable momentum among the domestic players, he noted. "From 2026 onwa

DGFT's floor prices on select bulk drugs aim to curb Chinese dumping, support PLI-backed manufacturers and lift domestic offtake, though capped medicine prices may limit cost pass-through

Cipla Ltd has inked an exclusive agreement with Pfizer India to market, distribute, and sell the latter's four brands across the country. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India, the two companies said in a joint statement on Friday. Pfizer will continue to manufacture, source, and supply these medicines to Cipla for India, they added. It is the first partnership between Pfizer and Cipla in India. The agreement aims to make Pfizer's medicines widely available across India by combining its well-established portfolio with Cipla's deep market reach, the statement said. Pfizer India Country President Meenakshi Nevatia said the partnership with Cipla will help expand the reach of its medicines to patients. "With Pfizer's legacy of breakthroughs, quality and innovation, and

The brokerage said Divis Laboratories is entering a stronger growth phase, supported by a robust H2FY26 pipeline and visibility for scale-up over the next two years.

Zydus will commercialise FYB206 in North America, while Formycon will lead development, regulatory filings and supply, with a US FDA filing expected soon

Proposed transaction will result in Biocon Biologics becoming a wholly-owned subsidiary of Biocon, simplifying the group structure, and strengthening the consolidated balance sheet

Exporters like Sun Pharma, Dr Reddy's may see 7-8% revenue lift, yet margins pressured by high raw material import costs

The UK has sealed a deal securing a 0 per cent tariff rate for all UK medicines exported to the US for at least 3 years, officials said Monday, in return for the UK spending more on new medicines. Under the deal, announced by officials on both sides, the United States government agreed to exempt UK-origin pharmaceuticals, pharmaceutical ingredients, and medical technology from import taxes. The Trump administration said that in return, UK drugs firms committed to invest more in the US and create more jobs. As part of the deal, the UK government said it will invest around 25 per cent more in new and effective treatments the first major increase in such spending in over two decades. Both sides hailed the deal as a win. This vital deal will ensure UK patients get the cutting-edge medicines they need sooner, and our world-leading UK firms keep developing the treatments that can change lives, Science and Technology Secretary Liz Kendall said. US Health Secretary Robert F. Kennedy Jr.

The Delhi facility offers over 60 advanced tests and aims to close critical gaps in respiratory diagnosis and care

Following the Chhindwara cough syrup tragedy, a CDSCO committee has advised consultations to phase out high-risk solvents in oral formulations

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly

The DCC has asked the Centre to address gaps in drug-standard enforcement, write to states on non-uniform norms and improve testing and regulatory infrastructure highlighted under the SHRESTH index